In conclusion, the current study elucidated the intricate mechanisms underlying ENO1-mediated immune evasion in BC and suggested targeting ENO1 as a novel therapeutic strategy to enhance antitumor immunity and improve clinical outcomes in BC patients. The gene discussed is ENO1; the disease is breast cancer.